CLAIMS

1. A modified IgG comprising: a feline IgG constant domain comprising at least one amino acid substitution relative to a wild-type feline IgG constant domain, wherein said substitution is at amino acid residue 247, numbered according to the Eu index as in Kabat, wherein said constant domain comprises the substitution P247I, P247L, or P247V, and wherein said wild-type feline IgG constant domain comprises the amino acid sequence that is at least 90% identical to the sequence of SEQ ID NO.: 1.

2. The modified IgG of claim 1, wherein the modified IgG has a higher affinity for FcRn than the IgG having the wild-type feline IgG constant domain.

3. The modified IgG of claim 1, wherein the modified IgG is a feline or felinized IgG.

4. The modified IgG of claim 1, wherein the IgG is $IgG1_a$.

5. The modified IgG of claim 1, wherein the IgG constant domain is a constant domain of $IgG1_a$.

6. The modified IgG of claim 1, wherein the IgG constant domain comprises an Fc constant region having CH3 domain.

7. The modified IgG of claim 1, wherein the IgG constant domain comprises an Fc constant region having CH2 and CH3 domain.

8. The modified IgG of claim 1, wherein the wild-type feline IgG constant domain comprises the amino acid sequence set forth in SEQ ID NO.: 1.

9. A pharmaceutical composition comprising the modified IgG of claim 1 and a pharmaceutically acceptable carrier.

10. A kit comprising the modified IgG of claim 1, in a container, and instructions for use.

11. A polypeptide comprising: a feline IgG constant domain comprising at least one amino acid substitution relative to a wild-type feline IgG constant domain, wherein said substitution is at amino acid residue 247, numbered according to the EU index as in Kabat, wherein said constant domain comprises the substitution P247I, P247L, or P247V, and wherein said wild-type feline IgG constant domain comprises the amino acid sequence that is at least 90% identical to the sequence of SEQ ID NO.: 1.

12. The polypeptide of claim 11, wherein the polypeptide has a higher affinity for FcRn than the polypeptide of the IgG having the wild-type feline IgG constant domain.

13. The polypeptide of claim 11, wherein the polypeptide is a polypeptide of a feline or felinized IgG.

14. The polypeptide of claim 11, wherein the IgG is $IgG1_a$.

15. The polypeptide of claim 11, wherein the IgG constant domain is a constant domain of $IgG1_a$.

16. The polypeptide of claim 11, wherein the IgG constant domain comprises an Fc constant region having CH3 domain.

17. The polypeptide of claim 11, wherein the IgG constant domain comprises an Fc constant region having CH2 and CH3 domain.

18. The polypeptide of claim 11, wherein the wild-type feline IgG constant domain comprises the amino acid sequence set forth in SEQ ID NO.: 1.

19. An antibody comprising: a feline IgG constant domain comprising at least one amino acid substitution relative to a wild-type feline IgG constant domain, wherein

said substitution is at amino acid residue 247, numbered according to the EU index as in Kabat, wherein said constant domain comprises the substitution P247I, P247L, or P247V, and wherein said wild-type feline IgG constant domain comprises the amino acid sequence that is at least 90% identical to the sequence of SEQ ID NO.: 1.

20. The antibody of claim 19, wherein the polypeptide has a higher affinity for FcRn than the polypeptide of the IgG having the wild-type feline IgG constant domain.

21. The antibody of claim 19, wherein the polypeptide is a polypeptide of a feline or felinized IgG.

22. The antibody of claim 19, wherein the IgG is $IgG1_a$.

23. The antibody of claim 19, wherein the IgG constant domain is a constant domain of $IgG1_a$.

24. The antibody of claim 19, wherein the IgG constant domain comprises an Fc constant region having CH3 domain.

25. The antibody of claim 19, wherein the IgG constant domain comprises an Fc constant region having CH2 and CH3 domain.

26. The antibody of claim 19, wherein the wild-type feline IgG constant domain comprises the amino acid sequence set forth in SEQ ID NO.: 1.

27. A pharmaceutical composition comprising the antibody of claim 26 and a pharmaceutically acceptable carrier.

28. A kit comprising the antibody of claim 26, in a container, and instructions for use.

29. A vector comprising the nucleic acid sequence encoding the amino acid sequence of antibody of claim 19, wherein the wild-type feline IgG constant domain comprises the amino acid sequence set forth in SEQ ID NO.: 1.

30. An isolated cell comprising the vector of claim 29.

31. A method of manufacturing an antibody or a molecule, the method comprising: providing the cell of claim 30; and culturing said cell.

32. A method of manufacturing an antibody, the method comprising: providing an antibody of any one of claims 19-17.

33. A fusion molecule comprising: a feline IgG constant domain comprising at least one amino acid substitution relative to a wild-type feline IgG constant domain, wherein said substitution is at amino acid residue 247, numbered according to the EU index as in Kabat, wherein said constant domain comprises the substitution P247I, P247L, or P247V, and wherein said wild-type feline IgG constant domain comprises the amino acid sequence that is at least 90% identical to the sequence of SEQ ID NO.: 1.

34. The molecule of claim 33, wherein the polypeptide has a higher affinity for FcRn than the polypeptide of the IgG having the wild-type feline IgG constant domain.

35. The molecule of claim 33, wherein the polypeptide is a polypeptide of a feline or felinized IgG.

36. The molecule of claim 33, wherein the IgG is $IgG1_a$.

37. The molecule of claim 33, wherein the IgG constant domain is a constant domain of $IgG1_a$.

38. The molecule of claim 33, wherein the IgG constant domain comprises an Fc constant region having CH3 domain.

39. The molecule of claim 33, wherein the IgG constant domain comprises an Fc constant region having CH2 and CH3 domain.

40. The molecule of claim 33, wherein the wild-type feline IgG constant domain comprises the amino acid sequence set forth in SEQ ID NO.: 1.

41. A pharmaceutical composition comprising the molecule of claim 33 and a pharmaceutically acceptable carrier.

42. A kit comprising the molecule of claim 33, in a container, and instructions for use.

43. The modified IgG of claim 1, wherein at least one of said mutations improves a biophysical property.

44. The modified IgG of claim 43, wherein said biophysical property is polyreactivity.

45. The polypeptide of claim 11, wherein at least one of said mutations improves a biophysical property.

46. The polypeptide of claim 45, wherein said biophysical property is polyreactivity.

47. The antibody of claim 19, wherein at least one of said mutations improves a biophysical property.

48. The antibody of claim 47, wherein said biophysical property is polyreactivity.

49. The molecule of claim 33, wherein at least one of said mutations improves a biophysical property.

50. The molecule of claim 49, wherein said biophysical property is polyreactivity.